Advert - Gilead Sciences Europe

• Date posted
  25 September 2020
• Sanction
  Advertisement,
• Case number/s
  AUTH/3282/11/19 - ViiV/Director v Gilead

For continuing to use a claim for Biktarvy (bictegravir/
emtricitabine/tenofovir) which had previously been ruled to be in
breach of the Code, Gilead Sciences Europe was ruled in breach
of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence
in, the pharmaceutical industry

Clause 9.1 - Failing to maintain high standards

Clause 29 - Failing to comply with an undertaking